The latest financial statement is for the year ending 2024-12-31.
| Cash Flow | 2024-12-31 |
|---|---|
| Decrease in loan to associate entities | 0 |
| Investment in associated company | 0 |
| Impact to cash resulting from deconsolidation | 0 |
| Purchase of property, plants and equipment | 263 |
| Cash acquired from acquisition of octomera (see note 3) | 139 |
| Impact to cash resulting from deconsolidation of obi, korea and belgium subsidiaries (see note 20) | 11 |
| Investment in long-term deposits | -500 |
| Net cash used in investing activities | 365 |
| Proceeds from transaction with redeemable non-controlling interest that do not result in a loss of control | 0 |
| Repayment of convertible loans and convertible bonds | 0 |
| Proceeds from issuance of shares due to exercise of options and warrants (net of transaction costs) | 2,556 |
| Proceeds from issuance of convertible loans | 75 |
| Repayment of short and long-term debt | 226 |
| Proceeds from issuance of loans payable | 6,060 |
| Grant received in respect of third party | 774 |
| Receipt from germfree (see note 13f) | 6,720 |
| Net cash provided by financing activities | 15,959 |
| Impairment of investment (see note 2) | 0 |
| Credit loss on convertible loan receivable | 0 |
| Net loss | -49,013 |
| Stock-based compensation | 3,194 |
| Convertible loans induced conversion expenses | 4,304 |
| Capital gain, net | 1,580 |
| Depreciation and amortization expenses | 2,086 |
| Credit loss net related to obi, korea and belgium subsidiaries | 2,049 |
| Effect of exchange differences on inter-company balances | 2,447 |
| Net changes in operating leases | -1,588 |
| Change in contingent consideration | -4,643 |
| Interest expense accrued on loans and convertible loans | -1,538 |
| Accounts receivable | -130 |
| Prepaid expenses, other accounts receivable | -2,262 |
| Inventory | -34 |
| Other assets | -43 |
| Related parties, net | 2 |
| Accounts payable | -1,279 |
| Accrued expenses and other payable | -820 |
| Employee and related payables | 1,300 |
| Deferred taxes, net | 2 |
| Impairment expenses (see note 2) | 18,338 |
| Share in loss of associated companies, net | -8 |
| Loss (gain) from deconsolidation of obi, korea and belgium subsidiaries in 2024 (octomera in 2023) | 4,480 |
| Loss from extinguishment in connection with convertible loan restructuring | -5,422 |
| Net cash used in operating activities | -17,076 |
| Net change in cash and cash equivalents and restricted cash | -752 |
| Net change in cash and cash equivalents and restricted cash | -752 |
| Effect of exchange rate changes on cash and cash equivalents | -40 |
| Cash and cash equivalents and restricted cash at beginning of year | 1,479 |
| Cash, cash equivalents and restricted cash at end of year | 687 |
Orgenesis Inc. (ORGS)
Orgenesis Inc. (ORGS)